They found that sarcopenia is more common in NAFLD patients compared to the non-NAFLD group (51.0% vs. 33.0%) and that it is a persistently independent risk factor for NAFLD in IBD patients (OR = 2.99; 95% CI 1.49–6.00; p = 0.002) and was maintained after adjustment for age, gender, obesity, diabetes mellitus, high blood pressure, and hyperuricemia (OR = 2.30; 95% CI 1.20–4.41; p = 0.012) and remained, after further adjustment for TG, HDL, and CRP (OR = 2.30; 95% CI 1.17–4.53; p = 0.016), and adjustment for small bowel resection history (OR = 2.23; 95% CI 1.13–4.41; p = 0.022) [23]. This evidence concerns the gene CRP and metabolic dysfunction-associated steatotic liver disease.